Diagnosis of Tuberculosis

Clinical Suspicion and Initial Evaluation

• The American Thoracic Society recommends considering TB in any patient with cough lasting ≥3 weeks, particularly when accompanied by evening fever, night sweats, weight loss, and anorexia 1, 2
• The Centers for Disease Control and Prevention suggest that the threshold for suspicion should be lower in high-prevalence areas and high-risk populations, such as HIV-infected, immunosuppressed, foreign-born from endemic countries, homeless, and incarcerated individuals 1, 3
• Hemoptysis is a symptom that may indicate TB, especially in patients with radiographic findings suggestive of TB, such as apical cavitary lesions and infiltrates 1, 4, 3

Diagnostic Algorithm for Pulmonary TB

• The Infectious Diseases Society of America recommends collecting three sputum specimens on different days for AFB smear microscopy and mycobacterial culture, as culture remains the gold standard for diagnosis 1, 2
• AFB smear microscopy using concentrated specimens with fluorescence microscopy is the preferred method, but negative AFB smears do not exclude TB due to false negatives 1, 4
• Mycobacterial culture is essential for species identification and drug susceptibility testing, and both liquid and solid culture should be performed on all specimens 1, 5

Radiographic Evaluation

• The American College of Radiology recommends that chest radiography is essential but cannot establish TB diagnosis alone, and classic findings include apical cavitary lesions, infiltrates, lymphadenopathy, and pleural effusions 3

Culture-Negative Pulmonary TB

• The American Thoracic Society suggests that when clinical and radiographic findings suggest TB but cultures remain negative, empiric four-drug therapy should be initiated, and reassessment should be done at 2 months 4

Testing for Latent TB Infection (LTBI)

• The Centers for Disease Control and Prevention recommend using tuberculin skin test (TST) and/or interferon-gamma release assay (IGRA) to diagnose LTBI, and a dual testing strategy is recommended in medium/high TB prevalence settings 6, 7
• The European Centre for Disease Prevention and Control suggests that IGRAs have advantages over TST, including no cross-reactivity with BCG vaccination and higher specificity in BCG-vaccinated populations 6

Special Populations

• The World Health Organization recommends that high-priority contacts, such as children <5 years old, HIV-infected individuals, and immunocompromised patients, require immediate evaluation, including TST/IGRA, chest X-ray, and repeat testing 8-10 weeks post-exposure if initial test negative 7

Common Pitfalls to Avoid

• The Infectious Diseases Society of America advises against relying on single negative sputum specimen, excluding TB based on negative AFB smears alone, delaying treatment in high-suspicion cases, using TST/IGRA to diagnose active TB, and assuming non-infectiousness after starting treatment 1, 2, 4, 3

AFB Smear Testing and TB Diagnosis

Immediate Testing Protocol

• The Centers for Disease Control and Prevention recommends that all patients with suspected pulmonary TB should have at least three sputum specimens collected on different days for AFB smear microscopy and mycobacterial culture, with nucleic acid amplification (NAA) testing performed on at least one respiratory specimen to enable diagnosis within 1-2 days rather than 1-2 weeks 8

Specimen Collection and Processing

• The Centers for Disease Control and Prevention suggests collecting respiratory specimens and processing them by liquefying, decontaminating, and concentrating before testing 8
• The Centers for Disease Control and Prevention recommends suspending specimens in sufficient buffer volume to ensure adequate sample for all planned tests: microscopy, culture, and NAA 8

Interpretation Algorithm Based on AFB Smear and NAA Results

• The Centers for Disease Control and Prevention recommends presuming TB and beginning four-drug anti-TB treatment immediately while awaiting culture results when AFB smear is positive and NAA is positive 8
• The positive predictive value exceeds 95% in this scenario, according to the Centers for Disease Control and Prevention 8
• The Centers for Disease Control and Prevention suggests using clinical judgment whether to begin treatment while awaiting culture when AFB smear is negative and NAA is positive 8
• The Centers for Disease Control and Prevention recommends considering testing an additional specimen with NAA to confirm the result—if two or more specimens are NAA-positive, presume TB pending culture 8
• The Centers for Disease Control and Prevention recommends testing for PCR inhibitors immediately and obtaining an additional specimen for NAA testing when AFB smear is positive and NAA is negative 8
• If inhibitors are detected, the NAA test provides no diagnostic help, and clinical judgment should be used to determine treatment initiation, according to the Centers for Disease Control and Prevention 8
• If no inhibitors are detected and a second specimen remains smear-positive but NAA-negative, the Centers for Disease Control and Prevention recommends presuming nontuberculous mycobacterial infection 8

Essential Caveats and Common Pitfalls

• The Centers for Disease Control and Prevention recommends never excluding TB based on negative AFB smears alone—culture remains the gold standard 8
• The Centers for Disease Control and Prevention suggests never delaying specimen collection and microbiologic testing to await NAA results 8
• Culture is mandatory for drug susceptibility testing and genotyping, so the Centers for Disease Control and Prevention recommends always reserving sufficient specimen portions for culturing 8
• The Centers for Disease Control and Prevention recommends that current NAA tests detect only 50-80% of AFB smear-negative, culture-positive pulmonary TB cases, so negative results do not exclude TB 8

Tuberculosis Diagnosis, Infectiousness, and Treatment Guidelines

Diagnosis and Initial Evaluation

• Adults presenting with a cough lasting ≥ 2–3 weeks together with fever, night sweats, weight loss, or hemoptysis should be promptly evaluated for tuberculosis. [CDC MMWR 1994] 9
• The recommended initial work‑up is: obtain a chest radiograph; if the image is suggestive of TB, collect three sputum specimens on separate days for acid‑fast bacilli (AFB) smear microscopy and mycobacterial culture. [CDC MMWR 1994] 9
• Patients with any of the following risk factors merit a lower diagnostic threshold and should be investigated for TB with the same algorithm:
   [CDC MMWR 1994] 9

Determining Infectiousness and Isolation

• A patient is considered potentially infectious when they are coughing, undergoing cough‑inducing procedures, or have a positive AFB sputum smear, especially if they have not yet started effective chemotherapy or are showing a poor therapeutic response. [CDC MMWR 1994] [10][11]
• Effective anti‑TB therapy reduces infectiousness by lowering cough frequency, sputum production, and bacterial load, but the exact time to become non‑infectious varies among individuals. [CDC MMWR 1994] [10][11]
• Some TB patients never become infectious, whereas those with unrecognized or inadequately treated drug‑resistant disease may remain infectious for weeks to months. [CDC MMWR 1994] [10][11]
• Isolation precautions must be maintained until three consecutive sputum smears collected on different days are negative and clinical improvement is evident. [CDC MMWR 1994] [12][10]11

Latent Tuberculosis Infection (LTBI) Management

• Before initiating LTBI therapy, active TB disease must be excluded through a thorough clinical history, physical examination, and chest radiograph. [Journal for ImmunoTherapy of Cancer 2019] 13

Drug‑Resistant Tuberculosis

• When drug‑resistant TB is suspected or confirmed, consultation with a TB expert is mandatory; treatment regimens should be tailored to the specific resistance pattern identified by susceptibility testing. [CDC MMWR 1994] 11
• Management of drug‑resistant TB involves second‑line agents that have greater toxicity, necessitating close monitoring for adverse effects. [Journal for ImmunoTherapy of Cancer 2019] 13